BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 23

Vertex Pharmaceuticals Inc

VRTXNASDAQ
Trade with Public
Trade with Public
$516.34
1.350.26%
가까이에: Sep 23, 5:00 PM EST
$517.00
0.660.13%
시간외: 7:40 PM EST
PRO
변동 이유?:Vertex Pharmaceuticals shares are trading higher after the company announce...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy
5Hold
1Sell
Consensus RatingBuy# Analysts27Avg. Consensus PT$543Upside to Avg. PT+5.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 11, 2026JP MorganJessica FyePT RaiseOverweight$515→$560
Sep 2, 2026Morgan StanleyTerence FlynnReinstatesOverweight$665
More with Benzinga EdgeGet Access

Analyst Ratings News

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.
Vandana Singh

PRO
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.
Benzinga Newsdesk

PRO
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved